← All trials
NCT06652438
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 13, 2025
- Primary completion
- May 13, 2028
- Completion date
- May 31, 2031
- First posted
- Oct 22, 2024
- Last posted
- Oct 30, 2024
- Enrollment
- 415
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- HOVON - Dutch Haemato-Oncology AssociationLead sponsor
- German-Austrian Acute Myeloid Leukemia Study GroupCollaborator
- United Kingdom AML Research NetworkCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.